European Medicines Agency (EMA) with the European Commission; national competent authorities in each member state
Is GHK-Cu (copper peptide) legal in European Union?
Not approvedNo EU marketing authorisation as a medicine; no specific EU medicines rule beyond the general one
Not approved as a medicine here.
GHK-Cu (copper tripeptide) has no marketing authorisation as a medicine in the EU and does not appear in the EMA dataset or the Union Register. Presented as a treatment, or given to people to change body functions, it falls under the EU definition of a medicinal product and would need authorisation. Under Article 6 of Directive 2001/83/EC, no medicine may be placed on the market without a marketing authorisation. This record does not assess its separate status as a cosmetic ingredient.
Last verified 2026-09-29 · how we verify
GHK-Cu (copper peptide) elsewhere
Sources (3)
- 01EMA medicines data (JSON report): human and veterinary medicines, with authorisation statusEuropean Medicines Agency · 2026-09-29 · accessed 2026-09-29
- 02Union Register of medicinal products for human useEuropean Commission · 2026-09-29 · accessed 2026-09-29
- 03Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text, 1 January 2025)European Union (EUR-Lex) · 2025-01-01 · accessed 2026-09-29